Table 1.

Baseline characteristics of study participants

All Active (n=88)All Placebo (n=57)Lanthanum (n=28)Sevelamer (n=30)Calcium (n=30)Siga
Demographics
 male50%49%54%50%47%1.00
 Caucasian81%79%82%80%80%1.00
 African-American10%11%7%7%17%
 age (years ± SD)68±1165±1270±1066±1268±120.72
 body mass index (kg/m2 ± SD)31±932±830±733±830±50.08
Comorbidity
 diabetes56%58%57%53%57%0.86
 CHF27%11%25%23%33%0.02
 CAD26%14%21%27%30%0.10
 HTN98%100%100%97%97%0.52
 MI12%5%4%23%10%0.25
 PVD24%19%21%20%30%0.55
 CVA8%4%14%3%7%0.48
 secondary hyperparathyroidism72%72%79%60%77%1.00
 hyperlipidemia89%93%86%97%83%0.57
 nontraumatic fracture17%18%7%23%20%1.00
Laboratory characteristics
 serum phosphorus (mg/dl ± SD)b4.2±0.44.2±0.44.2±0.44.2±0.44.2±0.40.47
 eGFR (ml/min ± SD)b32±8.130±8.533±7.932±9.130±7.10.32
 intact PTH (pg/ml ± SD)c78±5691±5287±5470±5676±580.05
 C-terminal FGF23 (RU/ml ± IQR)c227 (135–322)211 (140–278)230 (126–368)230 (143–362)219 (157–287)0.59
 intact FGF23 (pg/mL ± IQR)c120 (88–176)119 (95–169)111 (65–194)147 (95–202)114 (90–152)0.79
 1,25 dihydroxy vitamin Db25.7±9.427.2±10.326.9±10.024.7±10.325.5±8.10.69
 coronary artery calcium volume scorec262 (87–863)225 (18–737)216.5 (102–1694)362.5 (113–940.5)130 (13–645)0.33
 thoracic aorta calcium volume scorec583 (165–2282)496 (58–1539)1609 (98–5030)536 (351–2147)511 (50–2145)0.52
 abdominal aorta calcium volume scorec1551 (326–5377)1693 (212–6861)4035 (200–8578)1367 (519–3234)1468 (16–4328)0.70
 L2 to L4 bone mineral density (g/cm2)b111±34108±4599±22111±29120±420.45
 total urinary excretion of phosphorus (mg ± SD)b,d757±444805±359747±606769±350727±3540.20
 fractional excretion of phosphorus (% ± SD)b0.32±0.120.31±0.100.30±0.130.33±0.120.33±0.110.48
 total urinary excretion of calcium (mg ± SD)b,d55±4261±4753±4056±4358±430.69
  • CAD, coronary artery disease; CHF, congestive heart failure; CVA, cerebro-vascular disease; HTN, hypertension; MI, myocardial infarction; PVD, peripheral vascular disease.

  • a Significance. Fisher exact test for all active versus all placebo for binary measures and Wilcoxon rank sum tests for continuous measures.

  • b Mean.

  • c Median (IQR).

  • d Twenty-four hour urine measurements were adjusted for adequacy of collection using the mean of each individual urinary creatinine excretion.